Merck & Co., Inc.
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $65.0B
- Net income
- $18.3B
- Total assets
- $136.9B
- Market cap
- $298.3B
- Gross margin
- 74.8%
- Operating margin
- 32.4%
- Net margin
- 28.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $65.0B
- Cost of revenue
- $16.4B
- Gross profit
- $48.6B
- Operating expenses
- $27.6B
- Operating income
- $21.1B
- Income tax
- $2.8B
- Net income
- $18.3B
- EPS (basic)
- $7.30
- EPS (diluted)
- $7.28
Balance sheet
- Total assets
- $136.9B
- Current assets
- $43.5B
- Total liabilities
- $84.2B
- Current liabilities
- $28.3B
- Shareholders’ equity
- $52.7B
Cash flow
- Operating cash flow
- $16.5B
- Investing cash flow
- -$13.7B
- Financing cash flow
- -$1.9B
- Net cash flow
- $1.4B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $298.3B
- P/E ratio
- 16.4
- EPS (diluted)
- $7.28
- Dividend yield
- 2.84%
- Shares outstanding
- 2.5B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 20, 1949
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $18.3B in FY2025.
- Revenue grew 33% from FY2021 to FY2025.
- Gross margin of 74.8%, net margin 28.1%.
- Trading 4% below its 52-week high.
- Pays a dividend yielding about 2.84% annually.
- Valued at a price-to-earnings (P/E) ratio of 16.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Merck & Co., Inc..
Write a review
News about Merck & Co., Inc.
News & sentiment via Polygon.io
